The Acvr2b KI-PM mouse was developed by Taconic in 2026. This model was generated via point mutation of P119A, delV175-Q198, L530P. Exon 1 contains the translation initiation codon. The P119A, deletion of V175-Q198 and L530P mutations were introduced into exon 3, exon 4, and exon 10. Positive selection markers were flanked by FRT (Neomycin resistance – NeoR) and F3 (Puromycin resistance – PuroR) sites and were inserted into intron 1 and intron 7. The PuroR cassette also contains a tamoxifen-inducible Flpo recombinanse (FlpoERT2-PuroR). The targeting vector was generated using BAC clones from the C57BL/6J RPCI-23 BAC library and were transfected into the Taconic Biosciences C57BL/6NTac ES cell line. Homologous recombinant clones were isolated using double positive (NeoR and PuroR) and negative (Thymidine kinase – Tk) selections. The constitutive KI-PM allele was obtained after Flp-mediated removal of these selection markers. This KI-PM allele should express the mutated ACVR2B P119A, del V175-Q198, L530P protein which is identical to the human mature ACVR2B protein. The remaining recombination sites are located in non-conserved regions of the genome.

Source: Taconic Biosciences